Prof. Shu-Ching Hsu | Immunology of Infections | Best Researcher Award

Prof. Shu-Ching Hsu, National Health Research Institute/National Institute of Infectious Diseases and Vaccinology, Taiwan.

Prof. Shu-Ching Hsu is an Associate Investigator at the National Institute of Infectious Diseases and Vaccinology (NIIDV), NHRI, Taiwan. She earned her Ph.D. in Molecular Immunology and Signal Transduction from National Taiwan University and specializes in immunology, stem cell biology, and vaccine development. Prof. Hsu is widely recognized for her pioneering research on immune suppression, neutrophil biology, and the development of humanized mouse models to study immune responses in infectious diseases. Her work has significantly advanced immunotherapy, drug discovery, and our understanding of immune mechanisms in disease progression. She was honored with the Best Researcher Award for her exceptional contributions to the field of immunology and infectious diseases.

Author Profile

Scopus

🏫EARLY ACADEMIC PURSUITS

Dr. Shu-Ching Hsu earned her Ph.D. in Molecular Immunology and Signal Transduction from the Graduate Institute of Microbiology, National Taiwan University (1995–2000). Prior to this, she completed her M.S. in Molecular Biology and Immunology at National Yang-Ming University (1993–1995) and her B.S. in Microbiology from Soochow University (1989–1993).

💼 PROFESSIONAL ENDEAVORS

Dr. Shu-Ching Hsu has extensive professional experience in both research and academia. She is currently an Associate Investigator at the National Institute of Infectious Diseases and Vaccinology (NIIDV), NHRI, Taiwan (2013–present) and holds Associate Professor positions at National Chung Hsing University, National Defense University, and Kaohsiung Medical University (2013–present). Prior to her current roles, she served as an Assistant Investigator at the Vaccine Research and Development Center, NHRI, Taiwan (2005–2013). Dr. Hsu also completed two postdoctoral fellowships: one at Tulane University, USA (2002–2005) and another at Academia Sinica, Taiwan (2000–2002).

🔬RESEARCH INTERESTS

Dr. Shu-Ching Hsu’s research interests focus on human neutrophil biology and progenitor cell differentiation, as well as the development of humanized mouse models for advancing immunotherapy and drug discovery. She is also deeply engaged in understanding the mechanisms of immune suppression, particularly through myeloid-derived suppressive cells (MDSCs), and their role in disease progression. Additionally, Dr. Hsu explores stem cell-based therapies aimed at addressing infectious diseases, cancer, and various immune disorders.

🧠TECHNICAL SKILLS

Dr. Shu-Ching Hsu possesses expertise in stem cell biology, particularly in the development and use of humanized mouse models for immunotherapy and drug discovery. She is proficient in neutrophil biology, cell signaling, and understanding immune suppression mechanisms. Additionally, Dr. Hsu is skilled in the genetic modification of hematopoietic stem cells (HSCs) and the creation of stem cell-derived immune cell platforms for research and therapeutic applications.

📑 NOTABLE PUBLICATIONS 

“IL-10RA governs the expression of IDO in the instruction of lymphocyte immunity” 

Authors: Tai, T.-S., Hsu, D.-W., Yang, Y.-S., Wu, C.-H., Hsu, S.-C.
Publication Year: 2024
Citations: 0

Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein” 

Authors: Chiu, Y.-S., Wu, K.-J., Yu, S.-J., Wang, Y., Chen, Y.-H.
Publication Year: 2023
Citations: 1

“Correction: Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells” 

Authors: Chan, T.-S., Hsu, C.-C., Pai, V.C., Weaver, V.M., Tsai, K.K.
Publication Year: 2023
Citations: 0

The potential of adoptive transfer of Îł9δ2 T cells to enhance blinatumomab’s antitumor activity against B-cell malignancy” 

Authors: Chen, Y.-H., Wang, Y., Liao, C.-H., Hsu, S.-C.
Publication Year: 2021
Citations: 4

Index of cancer-associated fibroblasts is superior to the epithelial–mesenchymal transition score in prognosis prediction” 

Authors: Ko, Y.-C., Lai, T.-Y., Hsu, S.-C., Lin, C.-Y., Lin, S.-F.
Publication Year: 2020
Citations: 19

Downregulation of α-Synuclein Protein Levels by an Intracellular Single-Chain Antibody” 

Authors: Chen, Y.-H., Yu, S.-J., Wu, K.-J., Hoffer, B.J., Wang, Y.
Publication Year: 2020
Citations: 7

Prof. Shu-Ching Hsu | Immunology of Infections | Best Researcher Award

You May Also Like